|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-5.81/-6.58
|
企業價值
17.83B
|
資產負債 |
每股賬面淨值
30.99
|
現金流量 |
現金流量率
--
|
損益表 |
收益
6.75B
|
每股收益
23.62
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/01/11 11:23 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |